| Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
 Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
  
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 
  free 
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
  free 
  free 
 Warning:  file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=21609503&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
 in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
   English Wikipedia
 
 Nephropedia Template TP (
 
 Twit Text
 
 
 DeepDyve
 Pubget Overpricing
 | lüll   
 
 Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first  implications Ciarapica R; Miele L; Giordano A; Locatelli F; Rota RBMC Med  2011[May]; 9 (ä): 63Soft tissue sarcomas of childhood are a group of heterogeneous tumors thought to  be derived from mesenchymal stem cells. Surgical resection is effective only in  about 50% of cases and resistance to conventional chemotherapy is often  responsible for treatment failure. Therefore, investigations on novel therapeutic  targets are of fundamental importance. Deregulation of epigenetic mechanisms  underlying chromatin modifications during stem cell differentiation has been  suggested to contribute to soft tissue sarcoma pathogenesis. One of the main  elements in this scenario is enhancer of zeste homolog 2 (EZH2), a  methyltransferase belonging to the Polycomb group proteins. EZH2 catalyzes  histone H3 methylation on gene promoters, thus repressing genes that induce stem  cell differentiation to maintain an embryonic stem cell signature. EZH2  deregulated expression/function in soft tissue sarcomas has been recently  reported. In this review, an overview of the recently reported functions of EZH2  in soft tissue sarcomas is given and the hypothesis that its expression might be  involved in soft tissue sarcomagenesis is discussed. Finally, the therapeutic  potential of epigenetic therapies modulating EZH2-mediated gene repression is  considered.|DNA-Binding Proteins/*biosynthesis[MESH]|Enhancer of Zeste Homolog 2 Protein[MESH]|Epigenesis, Genetic[MESH]|Gene Expression Regulation[MESH]|Histones/metabolism[MESH]|Humans[MESH]|Methylation[MESH]|Polycomb Repressive Complex 2[MESH]|Sarcoma/*pathology[MESH]|Transcription Factors/*biosynthesis[MESH]
 |